Lynda R. Corrigan

Dr. Lynda R. Corrigan


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2019 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
LCLynda R. Corrigan
Lynda R. Corrigan
COConnor O’leary
Connor O’leary
JKJeska Kroes
Jeska Kroes
AFAbdul Rehman Farooq
Abdul Rehman Farooq
AHAnne Horgan
Anne Horgan
MOMiriam O’connor
Miriam O’connor

3 January 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MHMaeve A. Hennessy
Maeve A. Hennessy
MHMunzir Hamid
Munzir Hamid
NKNiamh M. Keegan
Niamh M. Keegan
LCLynda R. Corrigan
Lynda R. Corrigan
CGCaitriona Goggin
Caitriona Goggin
AHAnne M. Horgan
Anne M. Horgan
Older patients are underrepresented in the clinical trials that determine the standards of care for oncological treatment. We conducted a review to identify whether there have been age-restrictive inclusion criteria in clinical trials over the last twenty five years, focusing on patients with metastatic gastroesophageal cancer. A search strategy was developed encompassing Embase, PubMed and The Cochrane Library databases. Completed phase III randomised controlled trials evaluating systemic anti-cancer therapies in metastatic gastroesophageal malignancies from 1st January 1995 to 18th November 2020 were identified. These were screened for eligibility using reference management software (Covidence; Veritas Health Innovation Ltd). Data including age inclusion/exclusion criteria and median age of participants were recorded. The percentage of patients ≥ 65 enrolled was collected where available. The change over time in the proportion of studies using an upper age exclusion was estimated using a linear probability model. Three hundred sixty-three phase III studies were identified and screened, with 66 trials remaining for final analysis. The majority of trials were Asian (48%; n = 32) and predominantly evaluated gastric malignancies, (86%; n = 56). The median age of participants was 62 (range 18–94). Thirty-two percent (n = 21) of studies specified an upper age limit for inclusion and over half of these were Asian studies. The median age of exclusion was 75 (range 65–80). All studies prior to 2003 used an upper age exclusion (n = 12); whereas only 9 that started in 2003 or later did (17%). Among later studies, there was a very modest downward yearly-trend in the proportion of studies using an upper age exclusion (-0.02 per year; 95%CI -0.05 to 0.01; p = 0.31). Fifty-two percent (n = 34) of studies specified the proportion of their study population who were ≥ 65 years. Older patients represented only 36% of the trial populations in these studies (range 7–60%). Recent years have seen improvements in clinical trial protocols, with many no longer specifying restrictive age criteria. Reasons for poor representation of older patients are complex and ongoing efforts are needed to broaden eligibility criteria and prioritise the inclusion of older adults in clinical trials.

19 January 2018 in Current Problems in Cancer
Verified
Journal Article
Closed access
PDF file
LCLynda R. Corrigan
Lynda R. Corrigan
DBDara M. Bracken-Clarke
Dara M. Bracken-Clarke
AHAnne M. Horgan
Anne M. Horgan